Genotypes and phenotypes of CYP3A in Bangladeshi population

Clinica Chimica Acta

Volumn 412, Issue 7-8, 2011, Pages 531-536

  Maruf, Abdullah Al ^a   Ahmed, Maizbha Uddin ^a   Yasmin, Hasina ^a   Ullah, Md Ashik ^a   Azad, M A K ^a   Daly, Ann K ^b   Hasnat, Abul ^a  

^a UNIVERSITY OF DHAKA   (Bangladesh)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Bangladeshi subjects; CYP3A; Genotypes; PCR RFLP; Phenotypes

Indexed keywords

6BETA HYDROXYHYDROCORTISONE; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; GENOMIC DNA; HYDROCORTISONE;

ADULT; ALLELE; ARTICLE; BANGLADESH; CONTROLLED STUDY; FEMALE; GEL ELECTROPHORESIS; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HETEROZYGOSITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; POPULATION GENETICS; PRIORITY JOURNAL; SEQUENCE ANALYSIS; URINALYSIS; VOLUNTEER;

ADOLESCENT; ADULT; BANGLADESH; BASE SEQUENCE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP3A; FEMALE; GENOTYPE; HUMANS; HYDROCORTISONE; MALE; MOLECULAR SEQUENCE DATA; PHENOTYPE; POLYMERASE CHAIN REACTION; YOUNG ADULT;

EID: 79551496642     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.11.031     Document Type: Article

References (43)

1. Ruzilawati A.B., Mohd Suhaimi A.W., Gan S.H. Genetic polymorphisms of CYP3A4*18 allele is found in five healthy Malayan subjects. Clin Chim Acta 2007, 383:158-162.
2. Dandara C., Masimirembwa C.M., Magimba A., et al. Genetic polymorphism of CYP2D6 and CYP2C19 in East and Southern African populations including psychiatric patients. Eur J Clin Pharmacol 2001, 57:11-17.
3. Nebert D.W., Gonzalez F.J. P450 genes: structure, evolution and regulation. Annu Rev Biochem 1987, 56:945-993.
4. Kuehl P., Zhang J., Lin Y., et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001, 27:383-391.
5. Rais N., Chawla Y.K., Kohli K.K. CYP3A phenotypes and genotypes in North Indians. Eur J Clin Pharmacol 2006, 62:417-422.
6. Hirth J., Watkins P.B., Strawderman M., Schott A., Bruno R., Baker L.H. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res 2000, 6:1255-1258.
7. Schuetz J., Beach P., Guzelian P.S. Selective expression of cytochrome P450 CYP3A mRNAs in embyonic and adult human liver. Pharmacogenetics 1994, 5:11-20.
8. Eiselt R., Domanski T.L., Zibat A., et al. Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics 2001, 11:447-458.
9. Hustert E., Huberl M., Burk O., et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001, 11:773-779.
10. Rebbeck T.R., Jaffe J.M., Walker A.H., Wein A.J., Malkowicz S.B. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1999, 90:1225-1229.
11. Hsieh K.P., Lin Y.Y., Cheng C.L., et al. Novel mutations of CYP3A4 in Chinese. Drug Metab Dispos 2000, 29:268-273.
12. Dai Y., Iwanaga K., Lin Y.S., et al. In vitro metabolism of cyclosporine A by human kidney CYP3A5. Biochem Pharmacol 2004, 68(9):1889-1902.
13. Ged C., Rouillon J.M., Pichard L., et al. The increase in urinary excretion of 6 beta-hydroxy cortisol as a marker of human hepatic cytochrome P450IIIA induction. Br J Clin Pharmacol 1989, 28:373-387.
14. Lin Y.S., Lockwood G.F., Graham M.A., et al. In vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentrations. Pharmacogenetics 2001, 11:781-791.
15. Inagaki K., Inagaki M., Kataoka T., Sekido I., Gill M.A., Nishida M. A wide inter-individual variability of urinary 6β-hydroxycortisol to free cortisol in 487 healthy Japanese subjects in near basal condition. Ther Drug Monit 2002, 24:722-727.
16. Zhu B., Liu Z.Q., Chen G.L., et al. The distribution and gender difference of CYP3A activity in Chinese subjects. Br J Clin Pharmacol 2003, 55:264-269.
17. Kashuda A.D.M., Bertino J.S., Rocci M.L., Kulawy R.W., Beck D.J., Nafziger A.N. Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam. Clin Pharmacol Ther 1998, 64:269-277.
18. Kharasch E.D., Jubert C., Senn T., Bowdle T.A., Thummel K.E. Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance. J Clin Pharmacol 1999, 9:664-669.
19. Chen Z., Dunning L.A., Anderson K.E., Holtzman J.L., Zheng W. Within-person variability of urinary 6 beta-hydroxycortisol to cortisol ratios in Caucasian women. Steroids 2004, 69:67-70.
20. Tran J.Q., Kovacs S.J., McIntosh T.S., Davis H.M., Martin D.E. Morning spot and 24-hour urinary 6β-hydroxycortisol to cortisol ratios: intraindividual variability and correlation under basal conditions and conditions of CYP3A4 induction. J Clin Pharmacol 1999, 39:487-494.
21. Lykkesfeldt J., Loft S., Poulsen H.E. Simultaneous determination of urinary free cortisol and 6β-hydroxycortisol by high-performance liquid chromatography to measure human CYP3A activity. J Chromatogr B 1994, 660:23-29.
22. Ono T., Tanida K., Konishi H., Shimakawa H. High performance liquid chromatographic determination of 6β-hydroxycortisol in urine. Chem Pharm Bull Tokyo 1986, 34:2522-2527.
23. Daly A.K., Monkman S.C., Smart J., Steward A., Cholerton S. Analysis of cytochrome P450 polymorphisms. Meth Mol Biol 1998, 107:405-422.
24. King B.P., Leathart J.B.S., Mutch E., Williams F.M., Daly A.K. CYP3A5 phenotype-genotype correlations in a British population. Br J Clin Pharmacol 2003, 55:625-629.
25. Yin O.Q.P., Shi X., Tomlinson B., Chow M.S.S. Interindividual and intraindividual variability of the urinary 6β-hydroxycortisol/cortisol ratio in Chinese subjects: implications of its use for evaluating CYP3A activity. J Clin Pharmacol 2004, 44:1412.
26. Horsmans Y., Desager J.P., Harvengt C. Absence of CYP3A genetic polymorphism assessed by urinary excretion of 6β-hydroxycortisol in 102 healthy subjects on rifampicin. Pharmacol Toxicol 1992, 71:258-261.
27. Kleinbloesem C.H., van Brummelen P., Faber H., Danhof M., Vermeulen N.P.E., Breimer D.D. Variability in nifedipine pharmacokinetics and dynamics: a new oxidation polymorphism in man. Biochem Pharmacol 1984, 33:3721-3724.
28. Tateishi T., Watanabe M., Moriya H., Yamaguchi S., Sato T., Kobayashi S. No ethnic difference between Caucasian and Japanese hepatic samples in the expression frequency of CYP3A5 and CYP3A7 proteins. Biochem Pharmacol 1999, 57:935-939.
29. Yu K.S., Cho J.Y., Shon J.H., et al. Ethnic differences and relationships in the oral pharmacokinetics of nifedipine and erythromycin. Clin Pharmacol Ther 2001, 70:228-236.
30. Schellens J.H.M., Soons P.A., Breimer D.D. Lack of bimodality in nifedipine plasma kinetics in a large population of healthy subjects. Biochem Pharmacol 1988, 37:2507-2510.
31. Ng M.C.Y., Young R.P., Critchley J.A.J.H., Leung N.W.Y., Lau J.W.Y., Li A.K.C. Urinary 6β-hydroxycortisol excretion in Hong Kong Chinese patients with hepatocellular carcinoma and other chronic liver diseases. Cancer 1996, 77:1427-1433.
32. Hu Y.F., He J., Chen G.L., et al. CYP4A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population. Clin Chim Acta 2005, 253:187-192.
33. Balram C., Zhou Q., Cheung Y.B., Lee E.J.D. CYP3A5*3 and *6 single nucleotide polymorphisms in three distinct Asian populations. Eur J Clin Pharmacol 2003, 59:123-126.
34. Fukuena S., Fukudaa T., Maunea H., et al. Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population. Pharmacogenetics 2002, 12:331-334.
35. Ball S.E., Scatina J., Kao J., et al. Population distribution and effects on drug metabolism of a genetic variant in the 5β promoter region of CYP3A4. Clin Pharmacol Ther 1999, 66:288-294.
36. Sata F., Sapone A., Elizondo G., et al. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther 2000, 67:48-56.
37. Chowbay B., Zhou S., Lee E.J. An interethnic comparison of polymorphisms of the genes encoding drug-metabolizing enzymes and drug transporters: experience in Singapore. Drug Metab Rev 2005, 37:327-378.
38. Floyd M.D., Gervasini G., Masica A.L., et al. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European and African-American men and women. Pharmacogenetics 2003, 13:595-606.
39. Schirmer M., Toliat M.R., Haberl Michael, et al. Genetic signature consistent with selection against the CYP3A4*1B allele in non-African populations. Pharmacogenet Genomics 2006, 16(1):59-71.
40. Lamba J.K., Lin Y.S., Schuetz E.G., Thummel K.E. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002, 54:1271-1294.
41. Yamamoto T., Nagafuchi N., Ozeki T., et al. CYP3A4*18: it is not rare allele in Japanese population. Drug Metab Pharmacokin 2003, 18(4). [SNP24 (267)-SNP25 (268)].
42. Ando Y., Tateishi T., Sekido Y., et al. Re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1999, 91:1587-1590.
43. Fukushima-Uesaka H., Saito Y., Watanabe H., et al. Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population. Hum Mutat 2004, 23:100.